# ANI PHARMACEUTICALS, INC (ANIP) FY2026 Q2 Balance Sheet

- Company: ANI PHARMACEUTICALS, INC (ANIP)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-07, accession number 0001023024-26-000069
- Page: https://plicit.ai/financials/anip/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/anip-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,494,112,000 US dollars
- **Current assets**: 825,433,000 US dollars
- **Non-current assets**: 668,679,000 US dollars
- **Liabilities**: 896,900,000 US dollars
- **Current liabilities**: 283,655,000 US dollars
- **Non-current liabilities**: 613,245,000 US dollars
- **Equity**: 597,212,000 US dollars
- **Cash and cash equivalents**: 360,212,000 US dollars
- **Accounts receivable, net**: 274,469,000 US dollars
- **Inventories**: 143,149,000 US dollars
- **Prepaid expenses and other current assets**: 31,942,000 US dollars
- **Investment in equity securities**: 15,626,000 US dollars
- **Restricted cash**: 35,000 US dollars
- **Intangible assets, net**: 449,857,000 US dollars
- **Property and equipment, net**: 73,223,000 US dollars
- **Deferred tax assets, net**: 71,495,000 US dollars
- **Goodwill**: 62,480,000 US dollars
- **Other non-current assets**: 11,624,000 US dollars
- **Accounts payable**: 73,830,000 US dollars
- **Accrued royalties**: 55,830,000 US dollars
- **Returned goods reserve**: 44,013,000 US dollars
- **Accrued government rebates**: 41,392,000 US dollars
- **Accrued compensation and related expenses**: 27,154,000 US dollars
- **Current debt, net**: 21,329,000 US dollars
- **Accrued expenses and other**: 16,575,000 US dollars
- **Income taxes payable**: 3,532,000 US dollars
- **Convertible notes, net**: 309,009,000 US dollars
- **Debt, net**: 280,155,000 US dollars
- **Other non-current liabilities**: 15,535,000 US dollars
- **Contingent consideration**: 8,546,000 US dollars
- **Additional paid-in capital**: 620,249,000 US dollars
- **Retained earnings (Accumulated deficit)**: 31,104,000 US dollars
- **Common Stock, $0.0001 par value, 66,000,000 shares authorized; 23,853,338 shares issued and 22,961,423 shares outstanding at June 30, 2026; 23,112,577 shares issued and 22,491,281 shares outstanding at December 31, 2025**: 3,000 US dollars
- **Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively**: 0 US dollars
- **Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively**: 0 US dollars
- **Treasury stock, 891,915 shares of common stock, at cost, at June 30, 2026 and 621,296 shares of common stock, at cost, at December 31, 2025**: negative 53,817,000 US dollars
- **Accumulated other comprehensive (loss) income, net of tax**: negative 327,000 US dollars
- **Gross equity (calculated)**: 651,356,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.